{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":32,"n_cols":5,"rows_kept":32,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[12,2,12,3],[12,4,12,5],[13,2,13,3],[13,4,13,5],[14,2,14,3],[14,4,14,5],[15,2,15,3],[16,2,16,3],[17,2,17,3],[18,2,18,3],[19,2,19,3],[20,2,20,3],[26,2,26,3],[27,2,27,3],[29,2,29,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNISALENTO991000398429707536"]
[null,null,"Autore",null,"Andreani, Giulio"]
[null,null,"Titolo",null,"Fringe benefit e stock option : prassi contabile, trattamento fiscale e previdenziale / Giulio Andreani"]
[null,null,"Pubbl/distr/stampa",null,"Milano : EGEA, [2002]"]
[null,null,"ISBN",null,"8823830052"]
[null,null,"Descrizione fisica",null,"VIII, 240 p. ; 24 cm"]
[null,null,"Collana",null,"Impresa & professionisti. Fisco"]
[null,null,"Disciplina",null,"344.4505"]
[null,null,"Soggetti",null,"Stipendi e competenze accessorie - Guide pratiche"]
[null,null,"Lingua di pubblicazione",null,"Italiano"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,"2.","Record Nr.",null,"UNINA9911015964003321"]
[null,null,"Autore",null,"Reau Nancy S"]
[null,null,"Titolo",null,"Controversies in Hepatocellular Carcinoma / / edited by Nancy S. Reau, Amit G. Singal"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025"]
[null,null,"ISBN",null,"3-031-90225-4"]
[null,null,"Edizione",null,"[1st ed. 2025.]"]
[null,null,"Descrizione fisica",null,"1 online resource (548 pages)"]
[null,null,"Disciplina",null,"616.994"]
[null,null,"Soggetti",null,"Oncology"]
[{"$nulls":4},"Liver"]
[{"$nulls":4},"Physiology"]
[{"$nulls":4},"Drug delivery systems"]
[{"$nulls":4},"Hepatic Physiology"]
[{"$nulls":4},"Drug Delivery"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Section 1 - Risk Assessment and Chemoprevention -- Controversy 1 - Should All Patients with Hepatitis B Virus Undergo Hepatocellular Carcinoma Surveillance? -- Controversy 2 - Should Hepatocellular Carcinoma Surveillance Be Restricted to Those with Cirrhosis Among Patients With Hepatitis C? -- Controversy 3 - Should Hepatocellular Carcinoma Surveillance Be Performed in Patients with Noncirrhotic Nonalcoholic Steatohepatitis? -- Controversy 4 -Can Risk Stratification Models Be Used to Identify Patients without Cirrhosis who Might Benefit From Hepatocellular Carcinoma Surveillance? -- Controversy 5 - Should Hepatocellular Carcinoma Surveillance Be Performed Only for Patients with Decompensated Cirrhosis if They Are Listed for Liver Transplantation? -- Controversy 6 - Should Statins and Aspirin Be Used for Hepatocellular Carcinoma Chemoprevention in Patients with Cirrhosis? -- Section 2 - Liver Cancer Surveillance -- Controversy 7 - Should A Randomized Controlled Trial of Hepatocellular Carcinoma in Patients with Cirrhosis Be Performed? -- Controversy 8 - Should Contrast-Enhanced Computed Tomography and/or Magnetic Resonance Imaging Play a Routine Role in Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis? -- Controversy 9 - Should Biomarkers, Such as Alpha Fetoprotein, Play a Routine Role in Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis? -- "]
[{"$nulls":4},"Controversy 10 - Should Patients with Hepatitis C Virus Cirrhosis Undergo Hepatocellular Carcinoma Surveillance Indefinitely? -- Controversy 11 - Should Patients with Hepatitis C Virus Cirrhosis Undergo Hepatocellular Carcinoma Surveillance Indefinitely? -- Section 3 - Diagnosis -- Controversy 12 - Should All Liver Lesions in Patients with Cirrhosis Be Characterized and Reported Using Liver Imaging Reporting and Data System Criteria? -- Controversy 13 - Can Imaging Findings of Arterial Enhancement and Washout Still Represent a Benign Liver Lesion? -- Controversy 14 - Should Diagnostic Liver Biopsy Be Performed in Patients with Cirrhosis who Have Characteristic Imaging Features of Hepatocellular Carcinoma? -- Controversy 15 - Is Contrast-Enhanced Ultrasound Sufficiently Accurate to Be Used for Noninvasive Diagnosis of Hepatocellular Carcinoma? -- Section 4 - Prognosis -- Controversy 16 - Should Barcelona Clinic Liver Cancer Staging Be Used as the Preferred Staging System for Hepatocellular Carcinoma? -- Section 5 - TreatmentControversy 17 - Should Resection Be the Preferred Therapeutic Option for Patients Within the Milan Criteria and Compensated Cirrhosis Without Portal Hypertension? -- Controversy 18 - Should Liver Transplantation Be the Preferred Therapeutic Option in Patients with Compensated Cirrhosis and Portal Hypertension? -- Controversy 19 - Should Radiation-Based Therapy Be Considered in All Patients with Hepatocellular Carcinoma? -- Controversy 20 - Should Transarterial Radioembolization be the First-Line Therapy Compared to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma? -- Controversy 21 - Should All Patients Listed for Liver Transplantation Receive Bridging Therapy Before Transplant? -- Controversy 22 - Should Transplant Criteria Be Broadened Beyond United Network for Organ Sharing (UNOS) Downstaging Protocol to Include Larger Tumors? -- Controversy 23 - Should All Tyrosine Kinase Inhibitors Be Considered Equal for First-Line Hepatocellular Carcinoma Treatment? -- Controversy 24 - Should All Patients Be Considered for Locoregional Therapy Before Systemic Therapy? -- Controversy 25 - Should Direct-Acting Antivirals Be Given to Patients with Hepatocellular Carcinoma? -- Controversy 26 - Should Locoregional Therapy Be Given in Combination with Systemic Therapy? -- Controversy 27 - Should Patients with Decompensated Cirrhosis Receive Systemic Therapy? -- Controversy 28 - Would Effectively Downstaging Hepatocellular Carcinoma Allow All Patients to Be Considered for Liver Transplantation? -- Controversy 29 - Should Surgery Be Considered for Hepatocellular Carcinoma if Unable to Be Performed at Presentation? -- Controversy 30- Should Rapamune (Sirolimus)-Based Immunomodulation Be Given Post Transplant for Those Transplanted for or Found to Have Incidental Hepatocellular -- Controversy 31- Should Systemic Therapy Be Offered to all Patients Post Transplant for Those Transplanted for or Found to Have Incidental Hepatocellular Carcinoma? -- Controversy 32 - Should Post-Liver Transplantation Surveillance for Hepatocellular Carcinoma (HCC) Stop if There Is no HCC Recurrence After 5 Years?."]
[null,null,null,"Sommario/riassunto","This book is written for clinicians who care for patients with hepatocellular carcinoma (HCC) as well as health services researchers doing work in this area. The Editors and authors cover some of the emerging controversial topics that come up in HCC clinical practice and research. There are over 30 questions ranging from screening and diagnosis to therapeutics and survivorship. Chapters are begin with a controversy and the authors defend or refute the question. Comprehensive and unique, this book aims to help with management of this patient population."]